Form 4: Vaxcyte Director Teri Loxam Executes Stock Sales Under 10b5-1 Plan

Vaxcyte director Teri Loxam sold a total of 7,250 shares of common stock on January 15, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Teri Loxam, a director at Vaxcyte, Inc., executed multiple sales of common stock on January 15, 2025.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 18, 2024.
• A total of 7,250 shares were sold at various weighted-average prices ranging from $80.46 to $88.536.
• Loxam also exercised stock options to acquire 6,250 shares at a price of $22.70.
• Following these transactions, Loxam directly owns 7,175 shares of common stock.

Sentiment

Score: 5

Explanation: The document reflects routine insider trading activity under a pre-arranged plan, which is neither particularly positive nor negative. The sales are not unexpected, and the exercise of options is a normal part of executive compensation.

Positives

• The transactions were conducted under a pre-established 10b5-1 trading plan, indicating a planned and transparent approach to stock sales.
• The exercise of stock options at a lower price of $22.70 suggests a potential profit for the director.

Negatives

• The sale of 7,250 shares by a director could be perceived negatively by some investors, potentially signaling a lack of confidence in the company's future performance, although this is mitigated by the pre-arranged trading plan.

Risks

• Large sales by insiders, even under a 10b5-1 plan, can sometimes create short-term downward pressure on the stock price.
• The market may interpret these sales as a lack of confidence by a key insider, regardless of the pre-planned nature of the transactions.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and the use of 10b5-1 plans is a standard practice to avoid accusations of trading on non-public information. This filing is a routine disclosure of such activity.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among corporate insiders to manage their stock sales and avoid accusations of insider trading, similar to practices at companies like Moderna (MRNA) and BioNTech (BNTX).
• The reported weighted-average sale prices are within the typical range for stock transactions of this nature, and the disclosure is consistent with SEC requirements for Form 4 filings.
• The volume of shares sold is not unusual for a director's transactions, and the range of prices reflects normal market fluctuations.

Stakeholder Impact

• Shareholders may react to the stock sales, but the pre-planned nature of the transactions should mitigate any significant negative impact.
• The transactions do not directly impact employees, customers, or suppliers.

Key Dates

Keywords

Vaxcyte, Teri Loxam, insider trading, stock sales, Form 4, Rule 10b5-1, stock options, director